文献速递白血病

在标准诱导治疗中加入克拉屈滨可改善部分老年急性髓系白血病患者的结局:波兰成人白血病协作组(PALG)随机II期试验结果

Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.
PubMed 文献 · Am J Hematol · 2017-02-13

该随机II期试验比较DAC方案(柔红霉素+阿糖胞苷+克拉屈滨)与标准DA方案(柔红霉素+阿糖胞苷)在60岁以上初诊急性髓系白血病(AML)患者中的疗效与毒性,共纳入171例(DA组86例,DAC组85例)。DAC组完全缓解(CR)率有高于DA组的趋势(44% vs 34%;P=.19),但中位总生存未改善(DAC组8.6个月 vs DA组9.1个月;P=.64)。在60-65岁患者中DAC组CR率优于DA组(51% vs 29%;P=.02),且核型良好/中等的患者从加用克拉屈滨中总生存获益(P=.02)。两组血液学和非血液学毒性无差异。

要点

  • DAC组CR率44% vs DA组34%(P=.19),差异未达统计学显著。
  • DAC组中位总生存8.6个月 vs DA组9.1个月(P=.64),无显著差异。
  • 60-65岁患者中DAC组CR率51% vs DA组29%(P=.02)。

核心结论

  • 在标准DA诱导方案中加入克拉屈滨未显著改善老年AML患者总体CR率和总生存,但60-65岁患者及核型良好/中等患者可能获益。

研究设计与样本

  • 随机II期试验,纳入60岁以上初诊AML患者171例,随机分为DA组86例和DAC组85例。

主要发现

  • DAC组CR率44% vs DA组34%(P=.19),差异未达统计学显著。
  • DAC组中位总生存8.6个月 vs DA组9.1个月(P=.64),无显著差异。
  • 60-65岁患者中DAC组CR率51% vs DA组29%(P=.02)。
  • 核型良好/中等患者中加用克拉屈滨总生存获益(P=.02)。
  • 两组血液学和非血液学毒性无差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intensive induction chemotherapy using anthracycline and cytarabine backbone is considered the most effective upfront therapy in physically fit older patients with acute myeloid leukemia (AML). However, outcomes of the standard induction in elderly AML are inferior to those observed in younger patients, and they are still unsatisfactory. As addition of cladribine to the standard induction therapy is known to improve outcome in younger AML patients. The present randomized phase II study compares efficacy and toxicity of the DAC (daunorubicin plus cytarabine plus cladribine) regimen with the standard DA (daunorubicin plus cytarabine) regimen in the newly diagnosed AML patients over 60 years of age. A total of 171 patients were enrolled in the study (DA, 86; DAC, 85). A trend toward higher complete remission (CR) was observed in the DAC arm compared to the DA arm (44% vs. 34%; P = .19), which did not lead to improved median overall survival, which in the case of the DAC group was 8.6 months compared to in 9.1 months in the DA group (P = .64). However, DAC appeared to be superior in the group of patients aged 60-65 (CR rate: DAC 51% vs. DA 29%; P = .02). What is more, a subgroup of patients, with good and intermediate karyotypes, benefited from addition of cladribine also in terms of overall survival (P = .02). No differences in hematological and nonhematological toxicity between the DA and DAC regimens were observed.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Pluta A, Robak T, Wrzesien-Kus A, et al. Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. Am J Hematol. 2017. PMID: 28103640. doi:10.1002/ajh.24654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。